An estimated 2–3% of the world’s population is living with hepatitis C virus (HCV) – a condition that, when left untreated, can cause life-threatening damage to the liver.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
